A shorter regimen containing rifapentine and moxifloxacin can cure TB in four months.

TAG and AfroCAB are inviting applications from treatment activists and community leaders for a new cross-disease long-acting technologies community advisory board. The deadline to apply is 21 May 2021.

Treatment Action Group (TAG) is seeking a consultant to advance strategic policy-advocacy and resource mobilization efforts for TB research and development (R&D) in the context of the European Union (EU) and UK global development cooperation.

On 1 April 2021, Treatment Action Group (TAG) and the TB Europe Coalition co-hosted a webinar, Demanding a higher standard of TB care in Eastern Europe and Central Asia (EECA). The webinar marked the launch of TAG’s TB Activist’s Guides recently translated to Russian and featured speakers who discussed policy gaps and advocacy strategies for activists to demand access to the highest standard of care for TB diagnosis, treatment, and prevention in EECA.

For the third year, Treatment Action Group (TAG), with support from the IMPAACT4TB project, is organizing a self-guided Moodle online training course (2 May - 6 June 2021), TB Preventive Treatment | Fundamentals for Activists!, open to any members of TB civil society and communities. The course equips activists with everything they need to know to advocate for the highest-attainable standard of TB preventive treatment.

On Thursday, April 1, 2021, at 8:00 AM EDT / 2:00 PM CEST, Treatment Action Group (TAG) and TB Europe Coalition (TBEC) will co-host a webinar, “Demanding a Higher Standard of TB Care in Eastern Europe and Central Asia (EECA).”

On 21 January 2021, Treatment Action Group and partners conducted a webinar on how to engage in PEPFAR Country Operational Plans (COPs) advocacy and promote the prioritization of interventions that address HIV co-infections and advanced HIV disease (AHD).

TB and viral hepatitis co-infections and advanced HIV disease (AHD) put the lives of people living with HIV at risk, and interventions to address these must be prioritized by the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) and reflected in its funding allocations. The development of FY2021 Country Operational Plans (COPs) provides a critical opportunity for advocates to ensure that the latest developments in preventing, diagnosing, and treating co-infections and AHD are implemented within PEPFAR programs.

The report — Tuberculosis Research Funding Trends, 2005–2019 — presents new data on 2019 funding for TB research and development and analyzes trends in investment since 2005.

Treatment Action Group (TAG) launches newly available TB chapters of its 2020 Pipeline Report.